8-K: Celcuity Inc. Reports Q4 and Full Year 2024 Financial Results, Provides Clinical Program Update

Celcuity Inc. announces its Q4 and full year 2024 financial results, highlighting progress in its clinical trials and a strong cash position to fund operations through 2026.

Summary

• Celcuity Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company expects 2025 to be a transformational year with several clinical data readouts anticipated.
• Topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 trial is expected in Q2 2025.
• Topline data for the Phase 1b/2 trial in metastatic castration resistant prostate cancer is expected in late Q2 2025.
• Topline data for the PIK3CA mutant-type cohort of the VIKTORIA-1 trial is expected in Q4 2025.
• The VIKTORIA-2 Phase 3 trial remains on track to enroll its first patient in Q2 2025.
• Total operating expenses for Q4 2024 were $36.4 million, compared to $19.7 million for Q4 2023.
• Operating expenses for the full year 2024 were $113.3 million, compared to $66.2 million for the full year 2023.
• Net loss for Q4 2024 was $36.7 million, or $0.85 loss per share, compared to a net loss of $18.8 million, or $0.65 loss per share, for Q4 2023.
• Net loss for the full year 2024 was $111.8 million, or $2.83 loss per share, compared to a net loss of $63.8 million, or $2.69 loss per share, in 2023.
• Cash, cash equivalents, and short-term investments were approximately $235.1 million at the end of fiscal year 2024.
• This cash position is expected to fund current clinical development program activities through 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is experiencing increased losses and expenses, it has a strong cash position and is making progress in its clinical trials. The forward-looking statements are optimistic, but the financial results are concerning.

Positives

• Celcuity has a strong cash position of $235.1 million, expected to fund clinical development through 2026.
• The company is progressing with its clinical trials, with multiple data readouts expected in 2025.
• The VIKTORIA-1 and VIKTORIA-2 Phase 3 trials are advancing as planned.
• Encouraging preliminary overall survival data was presented from the Phase 1b trial at SABCS 2024.
• Site selection activities are completed for VIKTORIA-2, with approximately 200 sites expected to be activated.

Negatives

• The net loss increased significantly in both Q4 2024 and the full year 2024 compared to the previous year.
• Operating expenses have increased substantially, primarily due to increased R&D spending on clinical trials.
• The company is still operating at a loss, with a net loss per share of $2.83 for the full year 2024.

Risks

• Unforeseen delays in clinical trials could impact the timeline for data readouts and regulatory submissions.
• The company's ability to obtain and maintain regulatory approvals for its products is subject to uncertainty.
• The market acceptance of gedatolisib, if approved, is not guaranteed.
• The development of competing therapies and tools could impact Celcuity's market position.
• The company's ability to access capital upon favorable terms or at all is subject to market conditions and other factors.

Future Outlook

Celcuity expects 2025 to be a transformational year with multiple clinical data readouts, including topline data from the VIKTORIA-1 trial (PIK3CA wild-type and mutant cohorts) and the Phase 1b/2 trial in metastatic castration resistant prostate cancer. The company also remains on track to enroll the first patient for the VIKTORIA-2 Phase 3 trial in Q2 2025.

Management Comments

• We expect 2025 to be a transformational year for Celcuity as we anticipate reporting several clinical data readouts, including primary analysis for the PIK3CA wild-type cohort of the VIKTORIA-1 trial, said Brian Sullivan, CEO and co-founder of Celcuity.
• We expect to share topline data in Q2 2025.
• We also remain on track to enroll the first patient for our VIKTORIA-2 Phase 3 trial in Q2 2025.

Industry Context

Celcuity is focused on developing targeted therapies for oncology, specifically in breast and prostate cancer. The company's lead candidate, gedatolisib, targets the PI3K/AKT/mTOR pathway, which is a key signaling pathway in cancer. The company is competing with other pharmaceutical companies developing therapies targeting similar pathways, such as PI3K inhibitors and mTOR inhibitors. The results from Celcuity's clinical trials will be closely watched by investors and industry analysts to assess the potential of gedatolisib in these indications.

Comparison to Industry Standards

• The median overall survival of 77.3 months in treatment-naive patients with HR+, HER2advanced breast cancer in the Phase 1b trial compares favorably to published data for currently available firstor second-line standard-of-care treatment regimens.
• This suggests that simultaneously inhibiting the ER, CDK4/6, and PAM signaling pathways could be a promising clinical development strategy.
• Companies like Novartis (with ribociclib) and Eli Lilly (with palbociclib) have established CDK4/6 inhibitors as standard of care in HR+/HER2breast cancer.
• Celcuity's approach of combining gedatolisib with these agents aims to improve outcomes in patients who have progressed on or are resistant to these therapies.

Stakeholder Impact

• Shareholders: The increased net loss may negatively impact shareholder value in the short term, but progress in clinical trials could provide long-term benefits.
• Employees: Increased R&D spending and clinical trial activity may create opportunities for employees.
• Patients: Successful development of gedatolisib could provide a new treatment option for patients with breast and prostate cancer.
• Creditors: The company's strong cash position reduces the risk for creditors.

Next Steps

• Report topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 trial in Q2 2025.
• Enroll the first patient for the VIKTORIA-2 Phase 3 trial in Q2 2025.
• Report preliminary data for the Phase 1b/2 trial in metastatic castration resistant prostate cancer in late Q2 2025.
• Report topline data for the PIK3CA mutant-type cohort of the VIKTORIA-1 trial in Q4 2025.

Key Dates

Keywords

Celcuity, gedatolisib, VIKTORIA-1, VIKTORIA-2, breast cancer, prostate cancer, clinical trials, financial results, oncology, targeted therapies